MannKind plans to develop inhalable epinephrine; lawmakers accuse Mylan of evading paying higher Medicaid rebates; NICE rejects Roche’s cancer drug
The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.’s vote to exit the E.U.
Get the most out of
Register for free and enjoy unlimited access to: